Martínez Montiel, Pilar Casís Herce, Begoña Gómez Gómez, Gonzalo Jesús Masedo González, Ángeles Yela San Bernardino, Carmen Piedracoba Cadahia, Carlos Castellano Tortajada, Gregorio
Pharmacologic therapy for inflammatory bowel disease refractory to steroids. [revisión] - Clinical and experimental gastroenterology, 2015 - 8:257-69.
Formato Vancouver:
Martínez Montiel MP, Casis Herce B, Gómez Gómez GJ, Masedo González A, Yela San Bernardino C, Piedracoba C et al. Pharmacologic therapy for inflammatory bowel disease refractory to steroids. Clin Exp Gastroenterol. 2015 Aug 17;8:257-69.
PMID: 26316792
PMC4544729
Contiene 87 referencias
Although corticosteroids are an effective treatment for induction of remission in inflammatory bowel disease (IBD), many patients are dependent on or refractory to corticosteroids. This review is based on scrutinizing current literature with emphasis on randomized controlled trials, meta-analyses, and Cochrane reviews on the management of IBD refractory to corticosteroids. Based on this evidence, we propose algorithms and optimization strategies for use of immunomodulator and biologic therapy in IBD refractory to corticosteroids.
Pharmacologic therapy for inflammatory bowel disease refractory to steroids. [revisión] - Clinical and experimental gastroenterology, 2015 - 8:257-69.
Formato Vancouver:
Martínez Montiel MP, Casis Herce B, Gómez Gómez GJ, Masedo González A, Yela San Bernardino C, Piedracoba C et al. Pharmacologic therapy for inflammatory bowel disease refractory to steroids. Clin Exp Gastroenterol. 2015 Aug 17;8:257-69.
PMID: 26316792
PMC4544729
Contiene 87 referencias
Although corticosteroids are an effective treatment for induction of remission in inflammatory bowel disease (IBD), many patients are dependent on or refractory to corticosteroids. This review is based on scrutinizing current literature with emphasis on randomized controlled trials, meta-analyses, and Cochrane reviews on the management of IBD refractory to corticosteroids. Based on this evidence, we propose algorithms and optimization strategies for use of immunomodulator and biologic therapy in IBD refractory to corticosteroids.
